Advancing First-Line Treatment Strategies in Gastric and Esophageal Cancers
Panelists discuss how the 5-year survival data for nivolumab plus chemotherapy underscore its sustained efficacy as a first-line treatment, showing durable benefits over alternatives. Further research, including real-world evidence and broader clinical trials, is needed to validate its long-term impact across diverse patient populations and cancer subtypes.
- What insights do the 5-year survival data for nivolumab plus chemotherapy provide when considering its efficacy alongside other first-line treatments for these cancers?
- What additional research or real-world evidence might be needed to further solidify the role of nivolumab plus chemotherapy based on these findings?
Recent Videos
Related Content
Efficacy and Safety of Zolbetuximab in Gastric Cancer
Aiman Waheed, MBBS;Muhammad Numan Saleem, MBBS;Yash Shah, MD;Muhammad Hamza Gul, MBBS, MD;Helai Hussaini, MD;Abdul Baseer Wardak, MBBS
December 6th 2024Article
Zolbetuximab’s targeted action, combined with manageable adverse effects, positions it as a promising therapy for advanced gastric cancer.
